Sars-Cov-2 virus and vaccination; biological and statistical framework.
Expert Rev Vaccines
; 20(9): 1059-1063, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1348017
ABSTRACT
INTRODUCTION:
The Development of the SARS-CoV-2 virus vaccine and its update on an ongoing pandemic is the first subject of the world health agenda. AREAS COVERED First, we will scrutinize the biological features of the measles virus (MV), variola virus (smallpox virus), influenza virus, and their vaccines to compare them with the SARS-CoV-2 virus and vaccine. Next, we will discuss the statistical details of measuring the effectiveness of an improved vaccine. EXPERT OPINION Amidst the pandemic, we ought to acknowledge our prior experiences with respiratory viruses and vaccines. In the planning stage of observational Phase-III vaccine effectiveness studies, the sample size, sampling method, statistical model, and selection of variables are crucial in obtaining high-quality and valid results.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Immunity, Cellular
Type of study:
Observational study
/
Prognostic study
/
Qualitative research
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Expert Rev Vaccines
Journal subject:
Allergy and Immunology
Year:
2021
Document Type:
Article
Affiliation country:
14760584.2021.1965884
Similar
MEDLINE
...
LILACS
LIS